<p>Recursion Pharmaceuticals, Inc.（纳斯达克代码：RXRX - 获取免费报告）周一的交易量强劲。交易中共成交 9,916,028 股，较前一交易日的 11,771,491 股下降了 16%。该股最后交易价格为 5.68 美元，前一交易日收盘价为 5.76 美元。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>突然崛起：Recursion Pharmaceuticals 是 NVIDIA 的 AI 宠儿吗？</li>
</ul>
<p>RXRX 一直是多份分析师报告的主题。Leerink Partners 在 2 月 28 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 7.00 美元下调至 6.00 美元，并对该股给予 “市场表现” 评级。摩根士丹利在周四的研究报告中将 Recursion Pharmaceuticals 的目标价从 10.00 美元下调至 8.00 美元，并给予 “等权重” 评级。Cowen 在 2 月 28 日的研究报告中重申了对 Recursion Pharmaceuticals 的 “持有” 评级。KeyCorp 在 1 月 8 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 12.00 美元下调至 10.00 美元，并给予 “超配” 评级。最后，Needham &amp; Company LLC 在 4 月 8 日的研究报告中重申了 “买入” 评级，并对 Recursion Pharmaceuticals 的目标价设定为 11.00 美元。四位分析师对该股给予 “持有” 评级，两位分析师给予 “买入” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，平均目标价为 8.20 美元。</p>
<p><strong>查看我们对 RXRX 的最新分析</strong></p>
<h2>Recursion Pharmaceuticals 价格表现</h2>
<ul>
<li>生物科技处于边缘：两只潜力巨大的股票</li>
</ul>
<p>该股的 50 日移动平均价格为 6.83 美元，200 日移动平均价格也为 6.83 美元。该公司的市值为 21.9 亿美元，市盈率为-3.56，贝塔值为 1.00。公司的债务与股本比率为 0.04，流动比率为 4.35，速动比率为 4.35。</p>
<p>Recursion Pharmaceuticals（纳斯达克代码：RXRX - 获取免费报告）最近在 2 月 28 日发布了季度财报。公司报告季度每股收益（EPS）为-0.53 美元，低于分析师共识预期的-0.36 美元，差距为-0.17 美元。该季度的营业收入为 460 万美元，而分析师预期为 1904 万美元。Recursion Pharmaceuticals 的净利润率为-579.52%，股本回报率为-76.56%。该公司的收入同比下降了 57.8%。在去年同期，该公司每股收益为-0.42 美元。整体来看，股票分析师预计 Recursion Pharmaceuticals, Inc.在当前财年将发布-1.57 美元的每股收益。</p>
<h2>Recursion Pharmaceuticals 的机构交易</h2>
<ul>
<li>AI 制药：通往 AI 驱动药物投资的两条路径</li>
</ul>
<p>大型投资者最近增加或减少了对该股的持仓。Vanguard Group Inc.在第四季度将其在 Recursion Pharmaceuticals 的持仓增加了 40.1%。Vanguard Group Inc.目前拥有 34,009,994 股该公司的股票，价值 229,908,000 美元，此前在上个季度增持了 9,737,196 股。软银集团在第四季度购买了 Recursion Pharmaceuticals 的新股份，价值约为 99,152,000 美元。State Street Corp 在第三季度将其在 Recursion Pharmaceuticals 的持仓增加了 47.1%。State Street Corp 目前拥有 12,870,272 股该公司的股票，价值 84,815,000 美元，此前在上个季度增持了 4,120,685 股。Novo Holdings A S 在第四季度购买了 Recursion Pharmaceuticals 的新股份，价值约为 68,375,000 美元。最后，Geode Capital Management LLC 在第四季度将其在 Recursion Pharmaceuticals 的持仓增加了 12.1%。Geode Capital Management LLC 目前拥有 6,087,149 股该公司的股票，价值 41,160,000 美元，此前在上个季度增持了 655,238 股。89.06% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>关于 Recursion Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Recursion Pharmaceuticals, Inc.是一家临床阶段的生物技术公司，致力于通过整合生物学、化学、自动化、数据科学和工程等技术创新来解码生物学，以工业化药物发现。该公司开发的 REC-994 正在进行治疗脑血管畸形的二期临床试验；REC-2282 正在进行治疗神经纤维瘤病 2 型的二期/三期临床试验；REC-4881 正在进行治疗家族性腺瘤性息肉病的一期 b/二期临床试验；REC-3964 正在进行治疗艰难梭状芽胞杆菌感染的一期临床试验；REC-4881 正在进行治疗 AXIN1 或 APC 突变癌症的二期临床试验。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Recursion Pharmaceuticals 更好</li>
<li>5.00 美元以下的最佳股票</li>
<li>第一季度内部人士购买的三只大型股：买入、卖出或持有</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>三只在 2025 年市场低迷中逆势而上的新股</li>
<li>如何逐步购买便宜股票</li>
<li>三只以折扣价交易的高收益分红股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Recursion Pharmaceuticals 吗？</h2>
<p>在考虑 Recursion Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Recursion Pharmaceuticals 并不在名单上。</p>
<p>虽然 Recursion Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RXRX

<p>Recursion Pharmaceuticals（纳斯达克代码：RXRX）经历了强劲的交易量，共交易了 990 万股，较前一交易日下降了 16%。该股票收盘价为 5.68 美元，略低于前一交易日的收盘价 5.76 美元。分析师的评级不一，目标价范围从 6.00 美元到 11.00 美元不等。公司报告的季度每股收益为（0.53 美元），未达到预期，收入为 460 万美元，远低于预期。机构投资者持有该股票的 89.06%，显示出对这家专注于创新药物发现公司的强烈兴趣</p>

<p>Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares saw strong trading volume on Monday . 9,916,028 shares changed hands during trading, a decline of 16% from the previous session's volume of 11,771,491 shares.The stock last traded at $5.68 and had previously closed at $5.76.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.（纳斯达克代码：RXRX - 获取免费报告）周一的交易量强劲。交易中共成交 9,916,028 股，较前一交易日的 11,771,491 股下降了 16%。该股最后交易价格为 5.68 美元，前一交易日收盘价为 5.76 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?</li>
</ul>
<div class="lb-trans"><ul>
<li>突然崛起：Recursion Pharmaceuticals 是 NVIDIA 的 AI 宠儿吗？</li>
</ul>
</div><p>RXRX has been the topic of a number of analyst reports. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a &#34;market perform&#34; rating on the stock in a research note on Friday, February 28th. Morgan Stanley lowered their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Thursday. Cowen restated a &#34;hold&#34; rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, January 8th. Finally, Needham &amp; Company LLC restated a &#34;buy&#34; rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average price target of $8.20.</p>
<div class="lb-trans"><p>RXRX 一直是多份分析师报告的主题。Leerink Partners 在 2 月 28 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 7.00 美元下调至 6.00 美元，并对该股给予 “市场表现” 评级。摩根士丹利在周四的研究报告中将 Recursion Pharmaceuticals 的目标价从 10.00 美元下调至 8.00 美元，并给予 “等权重” 评级。Cowen 在 2 月 28 日的研究报告中重申了对 Recursion Pharmaceuticals 的 “持有” 评级。KeyCorp 在 1 月 8 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 12.00 美元下调至 10.00 美元，并给予 “超配” 评级。最后，Needham &amp; Company LLC 在 4 月 8 日的研究报告中重申了 “买入” 评级，并对 Recursion Pharmaceuticals 的目标价设定为 11.00 美元。四位分析师对该股给予 “持有” 评级，两位分析师给予 “买入” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，平均目标价为 8.20 美元。</p>
</div><p><strong>View Our Latest Analysis on RXRX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 RXRX 的最新分析</strong></p>
</div><h2>Recursion Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 价格表现</h2>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技处于边缘：两只潜力巨大的股票</li>
</ul>
</div><p>The stock's fifty day moving average price is $6.83 and its 200-day moving average price is $6.83. The firm has a market cap of $2.19 billion, a PE ratio of -3.56 and a beta of 1.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.</p>
<div class="lb-trans"><p>该股的 50 日移动平均价格为 6.83 美元，200 日移动平均价格也为 6.83 美元。该公司的市值为 21.9 亿美元，市盈率为-3.56，贝塔值为 1.00。公司的债务与股本比率为 0.04，流动比率为 4.35，速动比率为 4.35。</p>
</div><p>Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's revenue was down 57.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.42) EPS. As a group, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals（纳斯达克代码：RXRX - 获取免费报告）最近在 2 月 28 日发布了季度财报。公司报告季度每股收益（EPS）为-0.53 美元，低于分析师共识预期的-0.36 美元，差距为-0.17 美元。该季度的营业收入为 460 万美元，而分析师预期为 1904 万美元。Recursion Pharmaceuticals 的净利润率为-579.52%，股本回报率为-76.56%。该公司的收入同比下降了 57.8%。在去年同期，该公司每股收益为-0.42 美元。整体来看，股票分析师预计 Recursion Pharmaceuticals, Inc.在当前财年将发布-1.57 美元的每股收益。</p>
</div><h2>Institutional Trading of Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 的机构交易</h2>
</div><ul>
<li>AI Pharma: 2 Paths to AI-Powered Drug Investment</li>
</ul>
<div class="lb-trans"><ul>
<li>AI 制药：通往 AI 驱动药物投资的两条路径</li>
</ul>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after acquiring an additional 9,737,196 shares during the last quarter. Softbank Group CORP. purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $99,152,000. State Street Corp increased its holdings in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Novo Holdings A S purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $68,375,000. Finally, Geode Capital Management LLC lifted its holdings in Recursion Pharmaceuticals by 12.1% in the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock valued at $41,160,000 after acquiring an additional 655,238 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该股的持仓。Vanguard Group Inc.在第四季度将其在 Recursion Pharmaceuticals 的持仓增加了 40.1%。Vanguard Group Inc.目前拥有 34,009,994 股该公司的股票，价值 229,908,000 美元，此前在上个季度增持了 9,737,196 股。软银集团在第四季度购买了 Recursion Pharmaceuticals 的新股份，价值约为 99,152,000 美元。State Street Corp 在第三季度将其在 Recursion Pharmaceuticals 的持仓增加了 47.1%。State Street Corp 目前拥有 12,870,272 股该公司的股票，价值 84,815,000 美元，此前在上个季度增持了 4,120,685 股。Novo Holdings A S 在第四季度购买了 Recursion Pharmaceuticals 的新股份，价值约为 68,375,000 美元。最后，Geode Capital Management LLC 在第四季度将其在 Recursion Pharmaceuticals 的持仓增加了 12.1%。Geode Capital Management LLC 目前拥有 6,087,149 股该公司的股票，价值 41,160,000 美元，此前在上个季度增持了 655,238 股。89.06% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>About Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Recursion Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.是一家临床阶段的生物技术公司，致力于通过整合生物学、化学、自动化、数据科学和工程等技术创新来解码生物学，以工业化药物发现。该公司开发的 REC-994 正在进行治疗脑血管畸形的二期临床试验；REC-2282 正在进行治疗神经纤维瘤病 2 型的二期/三期临床试验；REC-4881 正在进行治疗家族性腺瘤性息肉病的一期 b/二期临床试验；REC-3964 正在进行治疗艰难梭状芽胞杆菌感染的一期临床试验；REC-4881 正在进行治疗 AXIN1 或 APC 突变癌症的二期临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Recursion Pharmaceuticals</li>
<li>Best Stocks Under $5.00</li>
<li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>3 Hot New IPOs Defying the 2025 Market Slump</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>3 High-Yield Dividend Stocks Trading at a Discount</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Recursion Pharmaceuticals 更好</li>
<li>5.00 美元以下的最佳股票</li>
<li>第一季度内部人士购买的三只大型股：买入、卖出或持有</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>三只在 2025 年市场低迷中逆势而上的新股</li>
<li>如何逐步购买便宜股票</li>
<li>三只以折扣价交易的高收益分红股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Recursion Pharmaceuticals 吗？</h2>
</div><p>Before you consider Recursion Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Recursion Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Recursion Pharmaceuticals 并不在名单上。</p>
</div><p>While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Recursion Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Recursion Pharmaceuticals（纳斯达克股票代码：RXRX）出现异常高的交易量 - 现在是买入的时机吗？